Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Probable cold-shock DeaD-box protein A homolog DeaD (ATP-dependent RNA helicase dead homolog) | 0.0077 | 0.5 | 0.5 |
Echinococcus granulosus | eukaryotic initiation factor 4A III | 0.0077 | 0.5 | 0.5 |
Onchocerca volvulus | Eukaryotic initiation factor 4A homolog | 0.0077 | 0.5 | 0.5 |
Trypanosoma cruzi | Eukaryotic initiation factor 4A-1 | 0.0077 | 0.5 | 0.5 |
Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.0077 | 0.5 | 0.5 |
Leishmania major | eukaryotic initiation factor 4a, putative | 0.0077 | 0.5 | 0.5 |
Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.0077 | 0.5 | 0.5 |
Entamoeba histolytica | DEAD/DEAH box helicase, putative | 0.0077 | 0.5 | 0.5 |
Schistosoma mansoni | DEAD box ATP-dependent RNA helicase | 0.0077 | 0.5 | 0.5 |
Plasmodium vivax | RNA helicase-1, putative | 0.0077 | 0.5 | 0.5 |
Echinococcus granulosus | eukaryotic initiation factor 4A | 0.0077 | 0.5 | 0.5 |
Plasmodium falciparum | eukaryotic initiation factor 4A | 0.0077 | 0.5 | 0.5 |
Treponema pallidum | ATP-dependent RNA helicase | 0.0077 | 0.5 | 0.5 |
Toxoplasma gondii | eukaryotic initiation factor-4A, putative | 0.0077 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0077 | 0.5 | 0.5 |
Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.0077 | 0.5 | 0.5 |
Giardia lamblia | Translation initiation factor eIF-4A, putative | 0.0077 | 0.5 | 0.5 |
Leishmania major | eukaryotic initiation factor 4a, putative | 0.0077 | 0.5 | 0.5 |
Trypanosoma cruzi | Eukaryotic initiation factor 4A-1 | 0.0077 | 0.5 | 0.5 |
Trypanosoma brucei | Eukaryotic initiation factor 4A-1 | 0.0077 | 0.5 | 0.5 |
Echinococcus multilocularis | eukaryotic initiation factor 4A III | 0.0077 | 0.5 | 0.5 |
Schistosoma mansoni | DEAD box ATP-dependent RNA helicase | 0.0077 | 0.5 | 0.5 |
Echinococcus multilocularis | eukaryotic initiation factor 4A | 0.0077 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
AbsAC40_uM (functional) | > 26 uM | PUBCHEM_BIOASSAY: Sustained Induction of HSF-1 Measured in Cell-Based System Using Plate Reader - 2038-07_Activator_Dose_CherryPick_Activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
EC50 (functional) | > 260 uM | PUBCHEM_BIOASSAY: Luminescence Cell-Based Dose Retest to Identify Potentiators of Heat Shock Factor 1 (HSF1). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493224] | ChEMBL. | No reference |
Potency (functional) | 10.4179 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 14.1254 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PubChem BioAssay. qHTS of PTHR Inhibitors: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.